DDInter1676 DDInter1026
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Larotrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Larotrectinib {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Larotrectinib may lead to a major life threatening interaction when taken with Pimozide